OCUL news & sentiment — OCULAR THERAPEUTIX, INC

APR 10·International Business Times AustraliaMed

Ocular Therapeutix Stock Surges 10% Past $9 on Fresh SOL-1 Data Presentations for AXPAXLI

Ocular Therapeutix Inc. (OCUL) saw its stock jump over 10% on Thursday, closing at $9.30, in anticipation of new positive data presentations from its SOL-1 Phase 3 trial for AXPAXLI, a treatment for wet age-related macular degeneration. If approved, AXPAXLI could offer a long-lasting, differentiated treatment option, potentially requiring fewer injections than current therapies. The company is also advancing other trials for diabetic retinal disease and has a strong "Strong Buy" consensus from analysts, with an average price target of $23.56.

MAR 20·TradingView

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

EyePoint Pharmaceuticals has filed a lawsuit against its competitor, Ocular Therapeutix, alleging that Ocular Therapeutix made false claims regarding its eye drug. The lawsuit highlights a legal dispute within the ophthalmology pharmaceutical sector between the two companies.

MAR 20·TipRanks

EyePoint Sues Ocular Therapeutix Over Alleged Defamation

EyePoint Pharmaceuticals has filed a lawsuit against Ocular Therapeutix, alleging defamation, commercial disparagement, and tortious interference due to false statements made by Ocular Therapeutix about EyePoint's lead retinal drug candidate, DURAVYU. EyePoint is seeking injunctive relief, a public retraction, and monetary damages. Spark, TipRanks’ AI Analyst, rates EYPT as Neutral due to strong program momentum offset by significant financial constraints, including widening losses and heavy cash burn.

$OCUL

Ocular Therapeutix Stock Surges 10% Past $9 on Fresh SOL-1 Data Presentations for AXPAXLI

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

EyePoint Sues Ocular Therapeutix Over Alleged Defamation

News on $OCUL